Bangladesh Pharmaceuticals & Healthcare Report

Published 09 June 2015

  • 100 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
$1,295.00
Bangladesh Pharmaceuticals & Healthcare Report

BMI View: Bangladesh ' s pharmaceutical and healthcare sector growth will continue to stand on robust long-term fundamentals, including population growth, rising inc omes, urbanisation and economic expansion. Moreover, the country ' s efforts to increase drug manufacturing capacity both for domestic supply and drug exports will be sustained in the years ahead. This favourable outlook is reflected in UK-drugmaker GlaxoSmithKline expected strategies to strengthen its presence in the country. However, current political tensions in Bangladesh are set to weigh on the country ' s full potential, increasing economic risks and business environment uncertainty over the coming quarters.

Headline Expenditure Projections

  • Pharmaceuticals: BDT154.24bn (USD1.99bn) in 2014 to BDT171.31bn (USD2.17bn) in 2015; +11.07% in local currency terms and +9.03% in US dollar terms. Forecast in line with last quarter.

  • Healthcare: BDT437.55bn (USD5.64bn) in 2014 to BDT492.57bn (USD6.24bn) in 2015; +12.6% in local currency terms and +10.5% in US dollar terms. Forecast revised upwards from last quarter.

Risk/Reward Index: In Q315, we have downgraded Bangladesh RRI score to 41.8 (out of 100) from 43.0 in the last quarter, based on lower market value growth indices. However, Bangladesh retains its ranking position in our RRI matrix, standing as the 15th most attractive market to pharmaceutical investors out of 19 markets in the Asia Pacific region. Bangladesh's score is driven by a large pharmaceutical market (market expenditure score of 10.0 out of 20) and rapid drug market expansion (sector value growth score of 8.4 out of 12), but dragged down by low levels of drug spending per capita (spending per capita score of 1.2 out of 12) and limited intellectual property protection (patent respect score of 1.4 out of 7).

Key Trends And Developments

April 2015

  • Bangladesh currently exports drugs to 107 countries, including Germany, the US, France, Italy, the UK, Canada, the Netherlands...

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Operational Risk
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Bangladesh 2011-2019)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Bangladesh 2011-2019)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Bangladesh 2011-2019)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Bangladesh 2011-2019)
19
Prescription Drug Market Forecast
20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Bangladesh 2011-2019)
21
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Bangladesh 2011-2019)
23
Generic Drug Market Forecast
24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Bangladesh 2011-2019)
25
OTC Medicine Market Forecast
26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Bangladesh 2011-2019)
27
Pharmaceutical Trade Forecast
28
Table: Pharmaceutical Trade Data And Forecasts (Bangladesh 2013-2019)
29
Table: Pharmaceutical Trade Data And Forecasts local currency (Bangladesh 2013-2019)
30
Key Risks To BMI's Forecast Scenario
31
Macroeconomic Forecasts
32
Economic Analysis
32
Table: Economic Activity (Bangladesh 2010-2019)
34
Industry Risk Reward Ratings
35
Asia Pacific Risk/Reward Index
35
Bangladesh Risk/Reward Index
41
Rewards
41
Risks
42
Market Overview
43
Industry Trends And Developments
44
Epidemiology
44
Healthcare Sector
45
Healthcare Sector Financing
50
Healthcare Infrastructure
51
Table: Healthcare Resources (Bangladesh 2009-2014)
51
Table: Healthcare Personnel (Bangladesh 2009-2014)
51
Table: Healthcare Activity (Bangladesh 2009-2014)
52
Table: Hospital And Beds, 2002-2006
53
Table: Public Primary Care Facilities, 1994-2004
53
Table: Medical Personnel By Type, 1995-2006
54
Research And Development
55
Table: Suggestions Made By University Of Dhaka's Faculty Of Pharmacy To Improve Pharmaceutical Research
56
Clinical Trials
57
Regulatory Development
59
Table: Steps To Establish A Pharmaceutical Manufacturing Unit And Obtain A Drug Manufacturing Licence
61
Intellectual Property Issues
61
Pricing And Reimbursement
63
Competitive Landscape
66
Pharmaceutical Industry
66
Company Developments
68
Pharmaceutical Distribution
69
Company Profile
70
Beximco Pharmaceuticals
70
Eskayef
73
Novartis
76
Renata
78
Sanofi
82
Square Pharmaceuticals
85
Demographic Forecast
88
Table: Population Headline Indicators (Bangladesh 1990-2025)
89
Table: Key Population Ratios (Bangladesh 1990-2025)
89
Table: Urban/Rural Population & Life Expectancy (Bangladesh 1990-2025)
90
Table: Population By Age Group (Bangladesh 1990-2025)
90
Table: Population By Age Group % (Bangladesh 1990-2025)
91
Glossary
93
Methodology
95
Pharmaceutical Expenditure Forecast Model
95
Healthcare Expenditure Forecast Model
95
Notes On Methodology
96
Risk/Reward Index Methodology
97
Index Overview
98
Table: Pharmaceutical Risk/Reward Index Indicators
98
Indicator Weightings
99

The Bangladesh Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Bangladesh Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Bangladesh pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Bangladesh, to test other views - a key input for successful budgeting and strategic business planning in the Bangladeshi pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Bangladeshi pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Bangladesh.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%